Pilot experience with continuous infusion alemtuzumab in patients with fludarabine‐refractory chronic lymphocytic leukemia
暂无分享,去创建一个
M. Keating | S. O'brien | R. Lapushin | W. Wierda | S. Faderl | A. Ferrajoli | M. Browning
[1] E. Kimby,et al. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. , 2004, Blood.
[2] R. Kurzrock,et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders , 2003, Cancer.
[3] J. Byrd,et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. , 2002, Blood.
[4] G. Hale,et al. Pharmacokinetics of CAMPATH-1H: assay development and validation. , 2002, Journal of immunological methods.
[5] H. Kantarjian,et al. Results of First Salvage Therapy for Patients Refractory to a Fludarabine Regimen in Chronic Lymphocytic Leukemia , 2002, Leukemia & lymphoma.
[6] W. Rowan,et al. Cross‐linking of the CAMPATH‐1 antigen (CD52) mediates growth inhibition in human B‐ and T‐lymphoma cell lines, and subsequent emergence of CD52‐deficient cells , 1998, Immunology.
[7] S. Tang,et al. Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. , 1996, Leukemia & lymphoma.
[8] T. Schnitzer,et al. CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. , 1996, British journal of rheumatology.
[9] G. Hale,et al. The CAMPATH-1 antigen (CDw52). , 1990, Tissue antigens.